ArticleFrontiers in medicine2026
Vitamin D screening and targeted supplementation delays liver fibrosis in patients with chronic liver disease: A prospective randomized controlled trial.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the effects of vitamin D screening and targeted supplementation on the progression of liver fibrosis in patients with chronic liver disease (CLD). Methods: A total of 60 inpatients with CLD admitted to the Department of Gastroenterology at Shifang People's Hospital between April 2024 and April 2025 were enrolled and randomly assigned to the study group (S group Results: At baseline, there were no significant differences in age, gender, disease etiology, disease duration, 25(OH)D Conclusion: Vitamin D screening and personalized supplementation effectively improved vitamin D status in patients with CLD and were associated with favorable reductions in serum liver enzyme levels, in addition to non-invasive surrogate markers of liver fibrosis. Given the limitations of this small single-center unblinded trial, which relied on indirect laboratory and elastographic indicators rather than histological endpoints, large, placebo-controlled studies are required to verify its clinical value before generalized clinical application. Trial registration: The study was registered in the Chinese Clinical Trial Registry (ChiCTR2600124218).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.